HCMSG - Hepatitis C Mentor & Support Group, Inc.

  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us
  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us

FDA Approves First Over-the-Counter Naloxone Nasal Spray

4/2/2023

0 Comments

 
Agency Continues to Take Critical Steps to Reduce Drug Overdose Deaths Being Driven Primarily by Illicit Opioids
For Immediate Release:  March 29, 2023 FDA  News Release

Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Today’s action paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online. 
The timeline for availability and price of this OTC product is determined by the manufacturer. The FDA will work with all stakeholders to help facilitate the continued availability of naloxone nasal spray products during the time needed to implement the Narcan switch from prescription to OTC status, which may take months. Other formulations and dosages of naloxone will remain available by prescription only. 
Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl. 

“The FDA remains committed to addressing the evolving complexities of the overdose crisis. As part of this work, the agency has used its regulatory authority to facilitate greater access to naloxone by encouraging the development of and approving an over-the-counter naloxone product to address the dire public health need,” said FDA Commissioner Robert M. Califf, M.D. “Today’s approval of OTC naloxone nasal spray will help improve access to naloxone, increase the number of locations where it’s available and help reduce opioid overdose deaths throughout the country. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price.” 

TO CONTINUE READING: https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray



0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    November 2023
    October 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021

    Categories

    All

    RSS Feed

Privacy Policy
Disclaimer:  Information given by Hepatitis C Mentor and Support Group is not a substitute for advice given by your physician or health care provider.  We do not endorse any doctor, hospital, medical group, or treatment.